awmsg logo



adalimumab (Humira®)


Reference No. 3118

Publication date:
04/01/2017


Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection
adalimumab (Humira®) 40 mg solution for injection


Company: AbbVie Ltd
BNF category: Gastro-intestinal system
NMG meeting date: 02/11/2016
AWMSG meeting date: 07/12/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3916
Ministerial ratification: 22/12/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Adalimumab (Humira) is recommended as an option for use within NHS Wales for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download